Indication
B-ALL
4 clinical trials
4 products
3 drugs
Clinical trial
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2019-04-03
Product
CD22-CARClinical trial
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2027-07-01
Drug
cyclophosphamideDrug
fludarabineClinical trial
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-12-01
Product
CD19/CD22 CAR T-CellsClinical trial
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2020-06-01
Drug
VarlilumabProduct
ACP-319